Hydroxypropyl beta-cyclodextrin compositions and methods
View Patent ↗This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.
1. A method for treating Niemann-Pick disease Type C in a human, the method comprising administering to the human a pharmaceutical composition comprising a mixture of hydroxypropyl beta-cyclodextrin molecules, wherein the mixture of hydroxypropyl beta-cyclodextrin molecules has an average molar substitution of 0.40 to 0.80, and the pharmaceutical composition is administered intrathecally or intracerebroventricularly in a dosage of about 600 mg to about 1500 mg.
2. The method of claim 1 , wherein the average molar substitution of the mixture of hydroxypropyl beta-cyclodextrin molecules is 0.58 to 0.68.
3. The method of claim 2 , wherein the average molar substitution of the mixture of hydroxypropyl beta-cyclodextrin molecules is 0.62.
4. The method of claim 1 , wherein the dosage is about 700 mg to about 1200 mg.
5. The method of claim 4 , wherein the dosage is about 800 mg to about 1000 mg.
6. The method of claim 5 , wherein the dosage is about 900 mg.
7. The method of claim 1 , wherein the pharmaceutical composition is administered once every week, once every two weeks, once every three weeks, once every month, once every two months, or once every three months.
8. The method of claim 7 , wherein the pharmaceutical composition is administered every two weeks.
9. The method of claim 1 , wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
10. The method of claim 9 , wherein the pharmaceutically acceptable carrier is an aqueous solution.
11. The method of claim 10 , wherein the aqueous solution is an isotonic saline solution.
12. The method of claim 1 , wherein intrathecal administration is via lumbar injection.
13. The method of claim 1 , wherein the human has Niemann-Pick disease Type C1 or Niemann-Pick disease Type C2.
14. A method for treating Niemann-Pick disease Type C in a human, the method comprising administering to the human a pharmaceutical composition comprising a mixture of hydroxypropyl beta-cyclodextrin molecules, wherein the mixture of hydroxypropyl beta-cyclodextrin molecules has an average molar substitution of 0.58 to 0.68, and the pharmaceutical composition is administered intrathecally or intracerebroventricularly in a dosage of 900 mg every two weeks.